Novo Nordisk's Rybelsus hasn't lived up to expectations, say analysts

The Danish drugmaker’s diabetes pill hasn’t reached the success that was predicted three years ago, to the disappointment of analysts.

Photo: Novo Nordisk / PR

Novo Nordisk’s Rybelsus, a diabetes pill, is far from becoming the huge sales success it was heralded as prior to launching -- a realization that is now disappointing analysts, reports Danish financial media Finans.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs